Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis

Nature Clinical Practice Rheumatology

Volumn 4, Issue 10, 2008, Pages 510-511

  Gladman, Dafna D ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENTHESITIS; HUMAN; INJECTION SITE REACTION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SELF INJECTION; SHORT SURVEY; SKIN MANIFESTATION;

EID: 53849117759     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0880     Document Type: Short Survey

References (5)

1. Bond SJ et al. (2007) Predictors for radiological damage in psoriatic arthritis: Results from a single centre. Ann Rheum Dis 66: 370-376
2. Gladman DD et al. (1998) Mortality studies in psoriatic arthritis: results from a single outpatient centre. II. Prognostic indicators for death. Arthritis Rheum 41: 1103-1110
3. Soriano ER and McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33: 1422-1430
4. Kaltwasser JP et al. (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50: 1939-1950
5. Saad AA et al. (2008) Risk and benefits of tumour necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35: 883-890